| Hypertensive disease
Benicar vs Benicar HCT
Side-by-side clinical, coverage, and cost comparison for hypertensive disease.Deep comparison between: Benicar vs Benicar Hct with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBenicar Hct has a higher rate of injection site reactions vs Benicar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Benicar Hct but not Benicar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Benicar
Benicar Hct
At A Glance
Oral
Daily
Angiotensin II receptor antagonist
Oral
Daily
ARB / thiazide diuretic
Indications
- Hypertensive disease
- Hypertensive disease
Dosing
Hypertensive disease (Adults) Starting dose 20 mg once daily; may increase to 40 mg once daily after 2 weeks if further blood pressure reduction needed; oral.
Hypertensive disease (Pediatric, 6 years and older) 10 mg once daily for patients weighing 20 to <35 kg; 20 mg once daily for patients weighing >=35 kg; oral tablet or extemporaneous suspension.
Hypertensive disease Starting dose 40/12.5 mg or 20/12.5 mg once daily depending on prior monotherapy; titrate up to 40/25 mg if needed.
Contraindications
- Co-administration of aliskiren in patients with diabetes
- Hypersensitivity to any component of BENICAR HCT
- Anuria
- Coadministration with aliskiren in patients with diabetes
Adverse Reactions
Most common (>1%) Dizziness
Postmarketing Asthenia, angioedema, anaphylactic reactions, vomiting, sprue-like enteropathy, hyperkalemia, rhabdomyolysis, acute renal failure, increased blood creatinine levels, alopecia, pruritus, urticaria
Most common (>2%) Dizziness, upper respiratory infection, hyperuricemia, nausea
Serious Hypotension, impaired renal function, hypersensitivity reactions, electrolyte and metabolic imbalances, acute myopia and secondary angle-closure glaucoma, systemic lupus erythematosus, sprue-like enteropathy
Postmarketing Asthenia, vomiting, hyperkalemia, rhabdomyolysis, alopecia, pruritus
Pharmacology
Olmesartan medoxomil is a selective AT1 subtype angiotensin II receptor antagonist that blocks vasoconstrictor effects of angiotensin II by selectively blocking its binding to the AT1 receptor in vascular smooth muscle, acting independently of angiotensin II synthesis pathways.
Olmesartan medoxomil selectively blocks angiotensin II binding to the AT1 receptor in vascular smooth muscle, inhibiting vasoconstriction independent of angiotensin II synthesis pathways; hydrochlorothiazide is a thiazide diuretic that directly increases renal excretion of sodium and chloride, reducing plasma volume to lower blood pressure.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Benicar
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (1/12)
Benicar Hct
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Benicar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Benicar Hct
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Benicar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Benicar Hct
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Benicar.
No savings programs available for Benicar Hct.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BenicarView full Benicar profile
Benicar HctView full Benicar Hct profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.